Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility

 
• By Bridget Silverman
  
The FDA's returning biologics center director touted his flexibility with randomized trials and accelerated approval. (Shutterstock)

More from Approvals

More from Product Reviews